Natures Sunshine Products Inc
- Last sale
- Nov 12, 2026 · -0.77%
- Market cap
- $178.31M
- 17.33M shares
- Filings
- 1,018
Q3 2026+5.7% FY25 yoy
Q3 2026+153.7% FY25 yoy
Q3 2026+23.1% FY25 yoy
Q3 2026derived+101.3% FY25 yoy
Q3 2026+165.0% FY25 yoy
Q3 2026+10.9% FY25 yoy
- $178.31M
- 12.2×
- 0.4×
- 1.0×
- 5.89%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $480,144,000 | reported | |
| FY 2024 | 2024-12-31 | $454,364,000 | reported | |
| FY 2023 | 2023-12-31 | $445,320,000 | reported | |
| FY 2022 | 2022-12-31 | $421,910,000 | reported | |
| FY 2021 | 2021-12-31 | $444,084,000 | reported | |
| FY 2020 | 2020-12-31 | $385,205,000 | reported | |
| FY 2019 | 2019-12-31 | $362,215,000 | reported | |
| FY 2018 | 2018-12-31 | $364,810,000 | reported | |
| FY 2017 | 2017-12-31 | $342,029,000 | reported | |
| FY 2016 | 2016-12-31 | $341,159,000 | reported | |
| FY 2015 | 2015-12-31 | $324,705,000 | reported | |
| FY 2014 | 2014-12-31 | $366,367,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $16.31M | $16.31M | — | 17.51M sh | −5.3% | 56.5% |
| FY2024 | — | $8.86M | $8.86M | — | 18.48M sh | −1.8% | 61.8% |
| FY2023 | — | $6.40M | $6.40M | — | 18.82M sh | −1.2% | 20.8% |
| FY2022 | $0.00 | $13.57M | $13.57M | $0.00 | 19.06M sh | −2.0% | — |
| FY2021 | $19.86M | $7.43M | $27.28M | $1.00 | 19.45M sh | −1.8% | 97.6% |
Segments
LineFY2025ShareChange
Asia$221.78M46%+6.7%
North America$143.61M30%+3.4%
Europe$93.13M19%+9.8%
Latin America and Other$21.62M4.5%−5.5%
Asia———
Europe———
Latin America and Other———
Other———
Total$480.14M
Pharmaceutical preparations
Natures Sunshine Products Inc is the 57th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
ORGOOrganogenesis Holdings Inc.$564.2M17.0%6.6%$125.3MHCMHUTCHMED (China) Ltd$548.5M13.0%83.3%$2.6BMIRMMirum Pharmaceuticals, Inc.$521.3M54.7%4.5%$6.1BBBIOBridgeBio Pharma, Inc.$502.1M126.3%144.4%$14.6BTVTXTravere Therapeutics, Inc.$490.7M110.5%5.2%$5.0B
NATRNatures Sunshine Products Inc (this company)$480.1M5.7%4.1%$178.3M
ZLABZai Lab Ltd$460.2M15.3%38.1%$29.3BARWRArrowhead Pharmaceuticals, Inc.$450.8M45.6%160.6%$6.7BINVAInnoviva, Inc.$411.3M14.7%65.9%$1.3BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Natures Sunshine Products Inc · CIK 275053 · Engraved from SEC EDGAR